| scholarly article | Q13442814 |
| P50 | author | Christine A. Denny | Q41138848 |
| Michael A Kiebish | Q98733403 | ||
| P2093 | author name string | Alessia Mastrodonato | |
| Josephine C McGowan | |||
| Collin Hill | |||
| Alexander Kitayev | |||
| Christina T LaGamma | |||
| Niven R Narain | |||
| Rebecca A Brachman | |||
| P2860 | cites work | Personalized medicine in major depressive disorder -- opportunities and pitfalls | Q24170133 |
| Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial | Q24629398 | ||
| A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression | Q24630153 | ||
| Role of kappa-opioid receptors in stress and anxiety-related behavior | Q26991739 | ||
| Increased Signaling via Adenosine A1 Receptors, Sleep Deprivation, Imipramine, and Ketamine Inhibit Depressive-like Behavior via Induction of Homer1a | Q27305254 | ||
| Prevention of Trauma and Stressor-Related Disorders: A Review | Q28083758 | ||
| Disorders of purines and pyrimidines | Q28304575 | ||
| Antidepressant effects of ketamine in depressed patients | Q29617327 | ||
| A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression | Q29617914 | ||
| Time-dependent metabolomic profiling of Ketamine drug action reveals hippocampal pathway alterations and biomarker candidates | Q30423149 | ||
| Arrest of adult hippocampal neurogenesis in mice impairs single- but not multiple-trial contextual fear conditioning | Q30474621 | ||
| Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants | Q30887852 | ||
| Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression | Q34112179 | ||
| Hippocampal memory traces are differentially modulated by experience, time, and adult neurogenesis. | Q34213505 | ||
| Clinical recognition and aspects of the cerebral folate deficiency syndromes | Q34322272 | ||
| Metabolic disorders of purine metabolism affecting the nervous system | Q34430614 | ||
| Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial | Q34661315 | ||
| Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats | Q34682154 | ||
| A single infusion of ketamine improves depression scores in patients with anxious bipolar depression | Q35607157 | ||
| Brain metabolomics in rats after administration of ketamine | Q35642701 | ||
| Glutamate metabolism in major depressive disorder | Q35756139 | ||
| Ketamine as a Prophylactic Against Stress-Induced Depressive-like Behavior | Q36249177 | ||
| Previous Ketamine Produces an Enduring Blockade of Neurochemical and Behavioral Effects of Uncontrollable Stress | Q36431977 | ||
| Identification and validation of urinary metabolite biomarkers for major depressive disorder | Q36508139 | ||
| Neuropsychiatric Symptoms in Inborn Errors of Metabolism: Incorporation of Genomic and Metabolomic Analysis into Therapeutics and Prevention | Q36703069 | ||
| New Hippocampal Neurons Mature Rapidly in Response to Ketamine But Are Not Required for Its Acute Antidepressant Effects on Neophagia in Rats. | Q36760914 | ||
| Effects of Ketamine on Metabolomics of Serum and Urine in Cynomolgus Macaques (Macaca fascicularis). | Q37269686 | ||
| Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants | Q37307160 | ||
| Purine and pyrimidine metabolism: Convergent evidence on chronic antidepressant treatment response in mice and humans | Q37330439 | ||
| Cortical gamma-aminobutyric acid and glutamate in posttraumatic stress disorder and their relationships to self-reported sleep quality | Q37700406 | ||
| Neurological disorders of purine and pyrimidine metabolism | Q37852735 | ||
| Metabolic syndrome in people suffering from posttraumatic stress disorder: a systematic review and meta-analysis. | Q38113807 | ||
| Metabolic syndrome and major depression | Q38150605 | ||
| Metabolic syndrome, activity of the hypothalamic-pituitary-adrenal axis and inflammatory mediators in depressive disorder | Q38224167 | ||
| The promise of biomarkers in diagnosing major depression in primary care: the present and future | Q38529746 | ||
| Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies | Q38787388 | ||
| Prophylactic Ketamine Attenuates Learned Fear | Q38995853 | ||
| Erratum: GTP-cyclohydrolase deficiency responsive to sapropterin and 5-HTP supplementation: relief of treatment-refractory depression and suicidal behaviour | Q39255679 | ||
| GTP-cyclohydrolase deficiency responsive to sapropterin and 5-HTP supplementation: relief of treatment-refractory depression and suicidal behaviour | Q39274193 | ||
| Targeted Metabolomic Pathway Analysis and Validation Revealed Glutamatergic Disorder in the Prefrontal Cortex among the Chronic Social Defeat Stress Mice Model of Depression | Q39418875 | ||
| Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial | Q41489870 | ||
| A novel urinary metabolite signature for diagnosing major depressive disorder | Q43827823 | ||
| Metabolomics: beyond biomarkers and towards mechanisms | Q46206242 | ||
| Ketamine modulates TRH and TRH-like peptide turnover in brain and peripheral tissues of male rats | Q46489874 | ||
| Neurometabolic Disorders: Potentially Treatable Abnormalities in Patients With Treatment-Refractory Depression and Suicidal Behavior. | Q46880731 | ||
| Discovery of serum protein biomarkers in drug-free patients with major depressive disorder | Q48057418 | ||
| Metabolite signature for diagnosing major depressive disorder in peripheral blood mononuclear cells | Q48064073 | ||
| Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy | Q48282047 | ||
| The evolving story of folate in depression and the therapeutic potential of l-methylfolate. | Q48566459 | ||
| The roles of purinergic signaling in psychiatric disorders. | Q50558520 | ||
| 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor? | Q67825075 | ||
| [Borderline neuropsychiatric disorders in purine metabolism disorders in children] | Q70100785 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1813-1821 | |
| P577 | publication date | 2018-03-29 | |
| P1433 | published in | Neuropsychopharmacology | Q2261280 |
| P1476 | title | Prophylactic ketamine alters nucleotide and neurotransmitter metabolism in brain and plasma following stress | |
| P478 | volume | 43 |
| Q97652778 | Divergence in the metabolome between natural aging and Alzheimer's disease |
| Q99201902 | Ketamine, but not guanosine, as a prophylactic agent against corticosterone-induced depressive-like behavior: Possible role of long-lasting pro-synaptogenic signaling pathway |
| Q89805466 | Metabolomics in Psychiatric Disorders: What We Learn from Animal Models |
| Q89838175 | Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions |
| Q64066957 | Prophylactic Ketamine Treatment Promotes Resilience to Chronic Stress and Accelerates Recovery: Correlation with Changes in Synaptic Plasticity in the CA3 Subregion of the Hippocampus |
| Q90631883 | Prophylactic efficacy of 5-HT4R agonists against stress |
| Q94954574 | Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine |
Search more.